FDA regulation of in vitro diagnostics: the changing US environment
This article was originally published in Clinica
Jonathan Kahan looks at some of the creative and important initiatives relating to the regulation of in vitro diagnostics (IVDs) which have taken place at the FDA and discusses the more general changes affecting IVD regulation in the US.
You may also be interested in...
FDA action awaits Sun’s manufacturing facility in Halol after it failed to adequately address GMP deviations, though India’s top-ranked drug firm appears to have effectively lowered its dependence on the site that has had a patchy compliance run.
In a surprise to the market, Dr Reddy’s and Hikma have prevailed in challenging six method-of-use patents shielding Amarin’s Vascepa in the US, opening the door for a potential at-risk launch that would likely be challenged by the originator.
Duo will study up to four novel preclinical targets identified by Sitryx that may lead to potential new drugs for autoimmune diseases, which Lilly would then commercialize.